← Research library

Endoluten: clinical report on a tissue-derived preparation

Comparison in people · 2011

What was studied
163 patients: 99 adjunctive Endoluten; 64 controls across four diagnostic subgroups.
Main finding
In the dyshormonal myocardial dystrophy subgroup, estradiol was 101.3 pmol/L after Endoluten and 79.1 pmol/L after usual care. The report assessed several diagnoses separately.

Estradiol in the dyshormonal myocardial dystrophy subgroup · 101.3 ± 7.2 pmol/L with Endoluten versus 79.1 ± 4.2 pmol/L with conventional care. Shared baseline 65.4 ± 5.2 pmol/L. · Table 2 marks p < 0.05 versus conventional care.

Reported findings and study design

163 patients across four diagnoses, 99 receiving adjunctive Endoluten and 64 conventional care. Courses were one to three capsules two to three times daily for 15–30 days.

Population or model 163 patients: 99 adjunctive Endoluten; 64 controls across four diagnostic subgroups.

Results · Medical Center report, PDF pages 94–95, Tables 1–2
MeasureResultComparison, timing and statistics
Estradiol in the dyshormonal myocardial dystrophy subgroup101.3 ± 7.2 pmol/L with Endoluten versus 79.1 ± 4.2 pmol/L with conventional care. Shared baseline 65.4 ± 5.2 pmol/L.Table 2 marks p < 0.05 versus conventional care.
Follicle-stimulating hormone in the same subgroup46.8 ± 3.9 versus 71.6 ± 6.3 IU/mL, in the source’s printed units. Shared baseline 89.3 ± 3.5.Table 2 marks p < 0.05 versus conventional care.

The subgroup outcomes are short-term hormone measurements. The report does not explain the allocation method.

Source for these results ↗ · Reviewed 2026-11-16

Study limitations and source details

Study limitations

  • Subgroups must not be pooled into one efficacy result. This oral-preparation report cannot inherit long-term Epithalamin mortality findings. The linked page commercially reproduces the report.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Source details

Institute report — commercial reproduction

Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.

Sources checked

Citation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Human comparative studyFull text available

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution). Endoluten: clinical report on a tissue-derived preparation Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards